Penicillin and Streptomycin Market

Penicillin and Streptomycin are two prominent drugs used in the treatment of diseases caused due to bacteria. Penicillin refers to a group of antibiotics such as Pencilillium V, Penicillium G. Penicillin was first derived from Penicillium. Streptomycin is a bactericidal which is widely used in the treatment of Tuberculosis, along with other drugs. Streptomycin is also used to control fire blight in fruit trees. The market for Penicillin is segmented on the basis of the product type, end user, route of administration and geography.Among the product segments, formulations hold a larger market share than the bulk (Active Pharmaceutical Ingredient) manufacturing. The market for Penicillin and Streptomycin is estimated to be $XX million in 2015. It is estimated to grow at a CAGR of XX% during 2016-2021. The driving force behind the growth is rising number of infectious diseases, growing investments in research and development, innovations and government regulations. Increasing demand for generics and high incidences of anti-microbial resistance are the major factors which will drive the growth and development of new products in this market. However, stringent government regulations creating entry barriers and expiry of patents are the major challenges faced by Penicillin and Streptomycin market.

Geographically, North America holds the highest market share for Penicillin and Streptomycin market followed by Europe. The highest growth is going to be witnessed in Asia Pacific region, in countries such as India, China and Australia. The reason behind the growth is large population base improving healthcare infrastructure, rising health awareness and high disposable income.

Major players in this market are:
Pfizer (U.S),
Novartis (Switzerland),
Johnson & Johnson (U.S),
AstraZeneca (U.K),
GlaxoSmithKline (U.K),
Eli Lily (U.S),
Sanofi-Aventis (France)
Bristol-Myers Squibb (U.S).

“1. Global Penicillin and Streptomycin – Market Overview
2. Executive Summary
3. Global Penicillin and Streptomycin – Market Landscape 
   3.1. Market Share Analysis
   3.2. Comparative Analysis
      3.2.1. Product Benchmarking
      3.2.2. End user profiling
      3.2.3. Patent Analysis
      3.2.4. Top 5 Financials Analysis
4. Global Penicillin and Streptomycin – Market Forces
   4.1. Market Drivers
   4.2. Market Constraints
   4.3. Market Challenges
   4.4. Attractiveness of the Industry
      4.4.1. Power of Suppliers
      4.4.2. Power of Customers
      4.4.3. Threat of New entrants 
      4.4.4. Threat of Substitution
      4.4.5. Degree of Competition
5. Global Penicillin and Streptomycin – Strategic Analysis
   5.1. Value Chain Analysis
   5.2. Opportunities Analysis
   5.3. Product/Market Life Cycle Analysis
6. Global Penicillin and Streptomycin– By Product Type
   6.1. Penicillin 
      6.1.1. Bulk 
      6.1.2. Dosage
   6.2. Streptomycin
      6.2.1. Bulk 
      6.2.2. Dosage
7. Global Penicillin and Streptomycin Market – By Route of Administration
   7.1. Oral
   7.2. Intramuscular 
   7.3. Intravenous 
8. Global Penicillin and Streptomycin Market – By Manufacturing process
   8.1. Natural
   8.2. Synthetic
   8.3. Semi-synthetic
9. Global Penicillin and Streptomycin Market – By End User
   9.1. Pharmaceuticals
   9.2. Hospitals
   9.3. Clinics/ ASC’s
10. Global Penicillin and Streptomycin Market – Geographic Analysis
   10.1. Introduction 
   10.2. Americas
      10.2.1. Canada
      10.2.2. USA
      10.2.3. Brazil
      10.2.4. Others
   10.3. Europe
      10.3.1. U.K.
      10.3.2. Germany
      10.3.3. France
      10.3.4. Spain
      10.3.5. Netherlands
      10.3.6. Others
   10.4. APAC
      10.4.1. China
      10.4.2. Japan
      10.4.3. India
      10.4.4. South Korea
      10.4.5. Australia
      10.4.6. Others
   10.5. ROW
11. Market Entropy
   11.1. New Product Launches
   11.2. M&As, Collaborations, JVs and Partnerships
12. Company Profiles (Overview, Financials, SWOT Analysis – Top 5 Companies, Developments, Product Portfolio)
   12.1. Abbot Laboratories
   12.2. Bristol Myers Squibb Co.
   12.3. Johnson & Johnson
   12.4. Pfizer
   12.5. Amgen
   12.6. Biogen Idec
   12.7. Celgine Corporation
   12.8. Merck & Co., Inc.
   12.9. Gilead Sciences Inc.
   12.10. Eli Lilly and Co
   12.11. Astra Zeneca
   12.12. Sanofi Aventis SA
   12.13. GlaxoSmithKline Plc
   12.14. Roche Pharmaceuticals
   12.15. Novartis AG
   12.16. Bayer HealthCare AG
   12.17. Toyama Chemical Co., Ltd
   12.18. Astellas Pharma Inc.
   12.19. MiddleBrook Pharmaceuticals
   12.20. Takeda Pharmaceutical Company
*More than 40 Companies are profiled in this Research Report, Complete List available on Request*
“”*Financials would be provided on a best efforts basis for private companies””
13. Appendix
   13.1. Abbreviations
   13.2. Sources
   13.3. Research Methodology
   13.4. Bibliography
   13.5. Compilation of Expert Insights
14. Disclaimer”